GoodRx Reports Better Than Expected Q4 Results 
<p><a href='https://financialmodelingprep.com/financial-summary/GDRX'>GoodRx Holdings, Inc. (NASDAQ:GDRX)</a> reported its Q4 earnings results last week, with EPS of $0.07 coming in better than the Street estimate of $0.05. Revenue was $184.1 million, beating the Street estimate of $178.67 million.</p>
<p>Management provided the initial 2023 guidance, estimating revenue to be in the range of $780-$790 million with a mid-20s adjusted EBITDA margin. The Street expected the company to generate $778 million in revenue with approximately a 24% margin.</p>
<p>For Q1, the company expects revenue in the range of $181-$183 million with a mid-20s margin, mostly in line with the Street estimates.</p>
<p>Management highlighted the new collaboration with Express Scripts which builds in GoodRx discount prices in the pharmacy benefits for all participating Cigna Health Plans with over 10 million lives.</p>

NASDAQ:GDRX